EUVIMEDEUVIMED entdecken
Crossref

Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat

Oishani Chatterjee, Debjeet Sur iD

Journal of Basic and Clinical Physiology and Pharmacology · 2024

DOI: 10.1515/jbcpp-2023-0254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology, 2024. Verfasst von Oishani Chatterjee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, India. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Psoriasis is a persistent autoimmune inflammatory condition that is primarily affecting the skin. Pioglitazone (PGZ), a peroxisome proliferator activated receptor gamma (PPARγ) agonist, has been reported to have anti-inflammatory effects. However, the role of PGZ in psoriatic disease remains unclear. In this study, we aimed to repurpose the use of the PGZ for the treatment of psoriasis.

Methods

To investigate its efficacy, we employed an imiquimod (IMQ)-induced rat model. Wistar rats are randomly allocated to four different groups. Group, I served as a negative control, Group II IMQ control, Group III was treated with pioglitazone hydrogel and Group IV received standard drug betamethasone cream. PASI score was monitored on every alternative day and on day 7 animals were sacrificed and histopathology of skin was performed. Level of nitric oxide (NO) and myeloperoxidase (MPO) was also performed using established methods.

Results

The results of the experiment revealed that treatment with PGZ significantly (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisRatsAnimalsPioglitazoneImiquimodRats, WistarSkinPeroxidaseDisease Models, Animal

Stichwörter der Autor:innen

imiquimodinflammationmyeloperoxidasenitric oxidepioglitazonepsoriasis

Substanzen

PioglitazoneImiquimodPeroxidase

Autor:innen und Institutionen

  • Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, India.

ORCID-Profile: Debjeet Sur

Zitieren

APA

Chatterjee, O., & Sur, D. (2024). Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat. Journal of Basic and Clinical Physiology and Pharmacology. https://doi.org/10.1515/jbcpp-2023-0254

Vancouver

Chatterjee O, Sur D. Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat. Journal of Basic and Clinical Physiology and Pharmacology. 2024. doi:10.1515/jbcpp-2023-0254

BibTeX
@article{Chatterjee2024,
  author = {Chatterjee, Oishani and Sur, Debjeet},
  title = {Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat},
  journal = {Journal of Basic and Clinical Physiology and Pharmacology},
  year = {2024},
  doi = {10.1515/jbcpp-2023-0254}
}
Kostenlos starten →